New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:55 EDTARWR, ISISArrowhead weakness related to Isis' competing HBV program, says Piper Jaffray
Arrowhead Research (ARWR) shares are lower after competitor ISIS Pharmaceuticals (ISIS) announced preclinical data on its antisense compound targeting hepatitis B virus. Piper anticipates Arrowhead will begin multi-dose ARC-520 Phase II studies in Q4 and reiterates its Overweight rating and $24 price target on Arrowhead.
News For ARWR;ISIS From The Last 14 Days
Check below for free stories on ARWR;ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
14:54 EDTARWRArrowhead Research November volatility elevated into Phase IIb trial data
Subscribe for More Information
07:36 EDTARWRArrowhead outlook positive, says RBC Capital
Subscribe for More Information
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use